Data were extracted for the longest follow-up period noted in studies that documented adverse events at various time points, ensuring that at least 80% of the participating patients were included. Our systematic review adheres to the Harms Checklist outlined by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses.22 We discovered a lack of sufficient evidence comparing the harms of medical cannabis to alternative pain management methods, such as opioids.
This difference (however), is https://audiokushhq.com/cannabis-at-music-events-rules-and-realities/ considered barely clinically significant.25,26 The classification of pain dictates that we approach the question of beneficial effects by subgrouping pain into various types. Unfortunately — MMJ is also similar to opioids in that robust data establishing long-term benefit for chronic pain are scarce. To think medical and recreational use of marijuana do not considerably overlap would be naive, and we should avoid taking the same path we took with opioids.
There is one product where it makes me more active… but then I’m hurting because I’ve overdone it and been moving all day. It is making a difference but not that much of one. ” 72 years — male The drops worked better, but I’m still trying to figure out what works for me. ” 61, male
Products with a higher percentage of THC are generally considered more effective for pain relief but carry a higher risk for psychotomimetic side effects. Unlike THC (CBD is not psychotomimetic), so it does not give the “high” and it can help reduce THC’s psychotomimetic properties when used in combination. “But the clinical evidence is weaker, in large part due to low quality studies with low sample size or short duration of treatment and sometimes patient population not well-defined.” Overall, these studies suggest that prenatal exposure to CBD is likely to alter the production of testosterone, the function of the male gonads, and the receptor ligand interactions in the brain of offsprings. In addition, these reports conclude that chronic pain costs between $560 and $635 billion annually in both medical expenses and lost productivity.
1. Population and Study Design
The mechanisms of peripheral CB2 in arthritic joints also demonstrate how local immune modulation influences central gain , Figure 5,. The release of anandamide from postsynaptic sites affects presynaptic CB1/TRPV1, which results in reduced transmitter release and alters the neural circuit polarization associated with central sensitization. These plasticity types (typically identified as either depolarization-induced suppression of excitation or inhibition), are notably evident in pain circuits within the spinal cord and cortex. CB1 receptors on presynaptic neurons are bound by Δ9-tetrahydrocannabinol (THC) (inhibiting the release of excitatory neurotransmitters), while CB2 receptors on macrophages are engaged, decreasing the production of proinflammatory cytokines.
Chronic pain affects between 50 and 116 million American adults (a staggering number that surpasses those affected by heart disease), cancer, and diabetes combined (Committee on Advancing Pain Research Care and Education, 2011; Nahin, 2015; NIH, 2020). Further clinical research appears to be well worth pursuing if it leads to a new class of drugs to complement existing painkillers or medications that could simultaneously relieve pain and nausea or appetite loss. In fact, for that reason the IOM team recommended that researchers undertake clinical studies of cannabinoid medications among cancer patients on chemotherapy and AIDS patients suffering from wasting or significant pain.
During the 1800s, more than 100 studies regarding medical cannabis were published by researchers in both the U.S. and Europe.7 Later, legal restrictions reduced its medical use. Cannabinoids ought to be viewed as supplementary treatments rather than primary options, intended for select patients who do not receive adequate relief from conventional therapies. The evidence does not support that opioids demonstrate superior short-term efficacy for neuropathic pain, indicating a lesser comparative benefit overall 102,103. In 2025 (a proposal was made to establish a new regulatory framework for CBD products), aiming to classify certain CBD items under the Natural Health Products (NHPs) category, which would impose strict labeling, licensing requirements, and set a THC limit of 0.001% 60,61.
It is suggested by the evidence that the analgesic effect of cannabis and cannabinoids results from a mixture of compounds and multiple receptor systems. This website serves solely for informational purposes and should not be regarded as medical advice — diagnosis, or treatment. According to researchers from UC San Diego published in the Journal of Cannabis Research, it is crucial to pay special attention to medicinal users, as they may constitute a vulnerable group in search of symptom alleviation. The average age at which they first used was 34, in contrast to 23 for combined users, who tended to be predominantly male. A new survey of over 4,000 cannabis users in California indicates that pain relief is the primary reason for medical cannabis use (followed by individuals seeking assistance with sleep), anxiety, and stress. The majority of the researchers are affiliated with Leafwell, an organization that assists patients in obtaining medical marijuana cards in jurisdictions where it is permitted.